The Goldman Sachs Group started coverage on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued ...
Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback